Background: Conventional medications for Crohn’s disease (CD) include anti-inflammatory drugs, immunosuppressants and corticosteroids. If an individual does not respond, or loses response to first-line treatments, then biologic therapies such as tumour necrosis factor-alpha (TNF-α) antagonists such as adalimumab are considered for treating CD. Maintenance of remission of CD is a clinically important goal, as disease relapse can negatively affect quality of life.


Adalimumab, Adverse Effects, Anti-Inflammatory Agents, Azathioprine, Crohn's Disease, Drug Therapy, Immunosuppressive Agents, Mercaptopurine, Mesalamine, Placebo, therapeutic use, Treatment Outcome

Read More